CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder

Chihiro Namatame, Tatsuro Misu, Yoshiki Takai, Shuhei Nishiyama, Ichiro Nakashima, Kazuo Fujihara, Masashi Aoki

研究成果: Article査読

抄録

Here we report 3 cases of neuromyelitis optica spectrum disorder (NMOSD), who were all treated with eculizumab and could be observed with monitoring serum C3, C4 and 50% hemolytic complement (CH50) before and after the treatment. Serum C3 and C4 were not dramatically changed during the treatment, in contrast serum CH50 level of each patient had diminished and kept under the detection limit after the treatment without clinical worsening, even in the situation of extending dosing. Serum CH50 level is useful to monitor the drug efficacy during eculizumab treatment.

本文言語English
論文番号e05899
ジャーナルHeliyon
7
1
DOI
出版ステータスPublished - 2021 1
外部発表はい

ASJC Scopus subject areas

  • General

フィンガープリント 「CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル